Dernières nouvelles pour Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics

Aeglea BioTherapeutics

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Spyre Therapeutics Inc

Kiniksa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.04 by 400 percent. This is a 134.29 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $122.54 million which missed the analyst consensus estimate of $123.38 million by 0.68 percent. This is a 46.93 percent increase over sales of $83.39 million the same period last year.

Earnings

News

KNSA

Kiniksa Pharmaceuticals Q4 2024 GAAP EPS $(0.12) May Not Be Comparable To $0.04 Estimate, Sales $122.54M Miss $123.38M Estimate

Biotech

General

ARWR

Arrowhead Pharmaceuticals Presented Preclinical Data On ARO-ALK7 At Keystone Symposia on Obesity and Adipose Tissue

Canaccord Genuity analyst David Hynes maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $190 to $220.

Price Target

Analyst Ratings

SNOW

Canaccord Genuity Maintains Buy on Snowflake, Raises Price Target to $220

Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.05) by 380 percent. This is a 27.27 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $42.22 million which missed the analyst consensus estimate of $42.69 million by 1.10 percent. This is a 66.71 percent decrease over sales of $126.84 million the same period last year.

Earnings Beats

Earnings Misses

CIFR

Cipher Mining Q4 2024 Adj EPS $0.14 Beats $(0.05) Estimate, Sales $42.22M Miss $42.69M Estimate

LVTX

LAVA Initiates Process To Review Strategic Options

Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.74 by 45.95 percent. This is a 47.95 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $201.27 million which beat the analyst consensus estimate of $201.25 million by 0.01 percent. This is a 19.51 percent increase over sales of $168.41 million the same period last year.

HRMY

Harmony Biosciences Q4 Adj $1.08 Beats $0.74 Estimate, Sales $201.27M Beat $201.25M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4369226-1&amp;h=785781941&amp;u=http%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.">Trevi Therapeutics, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF. Topline results continue to be expected in the first half of 2025.

TRVI

Trevi Therapeutics Completes Enrollment for Phase 2b Trial of Haduvio in Chronic Cough

Guidance

PSEG Sees FY25 Non-GAAP Operating Earnings $3.94-$4.06 vs $4.01 Est.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $64 price target.

Reiteration

URGN

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $64 Price Target

Public Service Enterprise Q4 2024 Adj. EPS $0.84 Beats $0.83 Estimate, Sales $2.465B Miss $2.539B Estimate

<ul>
<li>Transfer Agency Services Provided by IFDS in Ireland and Luxembourg to be Assumed by State Street and SS&amp;C</li>
</ul>

SSNC

State Street And SS&C To Overhaul IFDS Operations In Ireland And Luxembourg After 20-Year Partnership

On Tuesday, Alzamend Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) announced its plans to initiate the first of five phase 2 clinical studies of AL001. The first study, in healthy human subjects, is expected to commence in the second quarter of 2025.
The study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43809487/exclusive-alzamend-neuro-says-tesla-dynamic-completes-head-coil-to-measure-brain-structure-lithium-levels" rel="noreferrer noopener">of the clinical trial</a>.
The head coil will capture detailed images of lithium across the entire brain, making measuring its levels in different brain regions easier and helping determine the ideal dose of AL001 that offers better safety and effectiveness than lithium carbonate.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42059707/exclusive-alzamend-neuro-reveals-full-data-from-nonclinical-study-of-its-lead-alzheimers-drug-potential" rel="noreferrer noopener">EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential</a>
The coil will also scan the whole brain to map key areas and track how lithium moves, improving our understanding of its effects.
In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on lithium delivery in the brain compared to marketed lithium salts.
The study in healthy human subjects will serve as a baseline to evaluate AL001's targeted effectiveness and side effects in Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients.
Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.
Price Action: ALZN stock is up 0.87% at $0.89 during the premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43935516/asia-market-dips-while-europe-advances-crude-oil-climbs-amid-supply-concerns-gold-retreats-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia Markets Dip While Europe Advance, Gold Retreats &#8211; Global Markets Today While US Slept</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

ALZN

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025

EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Plans To Initiate The First Of Five Highly Anticipated Phase II Clinical Studies Of AL001, With The Study, In Healthy Human Subjects, Expected To Commence In Q2 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) with a Buy and maintains $20 price target.

TRDA

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

SLB Says It Is Legally Permitted To Close The ChampionX Transaction In The United States

Needham analyst Mike Matson reiterates Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and maintains $51 price target.

VCYT

Needham Reiterates Buy on Veracyte, Maintains $51 Price Target

Tech

Vontier's Study Shows A Modern Delivery Driver Manages Multiple Digital Systems Simultaneously

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Director of Design David Imai has left the EV company to join electric boat maker Arc Boats.
What Happened: Imai said in a post on Linkedin earlier this month that he will be joining Arc Boats later in February as Chief Designer. As of today, Imai has already changed his job description. 
According to Imai&#8217;s LinkedIn profile, he joined Tesla in 2011 after having worked for over 4 years with General Motors. He joined as a car designer at Tesla and was primarily responsible for the exterior design of production cars. He became director of design in August 2019 and held on to the position until he left the company. 
Imai&#8217;s is not the sole departure from Tesla&#8217;s design team in recent months. Bernard Lee left his position as Senior Manager of Vehicle Design in November.
Lee was part of Tesla from October 2008 and left the company in 2018 but joined back in June 2020, according to his LinkedIn profile. Last year, he was the senior exterior design manager for the refreshed Model 3 as well as the Cybercab demo and production vehicle. 
Why It Matters: The departures come as the company is gearing up for new products. 
Tesla in January also said that preparations are underway across its existing factories for the launch of new products including more affordable models. The start of production of new models is slated for the first half of 2025.
The company has also begun hiring for the production of Cybercab which is<a href="https://www.benzinga.com/tech/25/02/43906182/tesla-begins-hiring-for-cybercab-manufacturing-as-elon-musk-led-ev-giant-prepares-for-robotaxi-rollout"> slated to start in 2026.</a> 
In an interview published earlier this week, Tesla executive Lars Moravy also said that the company is looking to refresh the design of its Model S and X cars later this year as well. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43909679/tesla-cybercab-will-have-no-stainless-steel-panels-and-will-not-be-painted-either-says-senior-company-exec" target="_blank" rel="noreferrer noopener">Tesla's Cybercab To Ditch Stainless Steel And Paint, Says Senior Company Exec: Here's How It Will Get Its Signature Gold Look</a></li>
</ul>
Photo courtesy: Shutterstock

TSLA

Elon Musk-Led Tesla Loses Another Key Designer As David Imai Heads To Arc Boats

CLWT

Euro Tech's PACT Lands $2.2M Contracts For Industrial And Maritime Water Treatment Solutions In China

WIIM

DOCN

DigitalOcean Holdings shares are trading higher after the company reported better-than-expected Q4 Adj. EPS and sales.

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Comments

Spyre Therapeutics

Actualités

Dernières nouvelles pour Spyre Therapeutics (NASDAQ:SYRE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL